Atherosclerosis is one of the main problems in modern medical practice. This multifactorial disease
can remain asymptomatic for a long time before manifesting itself in cardiovascular disorders, causing ischemic
heart disease, myocardial infarction and even sudden death. Many synthetic drugs have been developed to reduce
the symptoms of atherosclerosis, however, their efficacy in terms of reduction of atherosclerotic lesions progression
is a matter of debate. Adverse effects of the exiting therapy should also be taken into account. The development
of cellular models and improved understanding of the mechanisms of atherogenesis at the vascular wall
level helped establishing the “direct anti-atherosclerosis therapy” approach. In this approach, the decrease of
intracellular lipid deposition and atherogenicity of human blood serum are considered primary (direct) antiatherosclerotic
effects. Screening of synthetic and natural substances for anti-atherosclerotic activity revealed a
number of botanicals that could be used for direct anti-atherosclerotic therapy to treat early-stage atherosclerosis.
As a result, 3 novel non-pharmaceutical products were developed (Allicor, Inflaminat and Karinat). Studies on in
vitro and ex vivo models of atherogenesis confirmed their anti-atherosclerotic and anti-atherogenic activities and
safety in patients. Clinical studies of Allicor, Inflminat and Karinat were carried out in subjects with diagnosed
early stage atherosclerosis, demonstrating a clinically significant anti-atherosclerotic effect of the drugs. In this
overview, we will present the complete process of the development of novel non-pharmaceutical products and
report the results obtained in the conducted pre-clinical and clinical studies of these medications.
Keywords: Anti-atherosclerotic therapy, serum atherogenicity, cellular models, clinical trials, non-pharmaceutical products.
Rights & PermissionsPrintExport